Quality Comes First

          

APAC MARKETS

We seek to advance highly specialised and scientifically valuable fields to elevate the standard of healthcare.

Discover more about Menarini Group

For over 30 years, Menarini has been driving research and development to deliver innovative and effective medicines and healthcare solutions for patients affected by serious health conditions.

Gain a single point of entry to all major APAC markets with a direct presence in 13 key markets.

Sharing your partnering idea

Leverage our omni-channel approach to grow your brand across Asia Pacific.

MARKETS

The healthcare sector in Asia Pacific is rapidly growing. As part of the world’s leading Italian biopharmaceutical company, Menarini AP has a strong presence in 13 key markets across the region.

As a partner of choice for numerous global healthcare companies, we engage in the entire pharmaceutical development lifecycle to tap growth opportunities and grow their brand footprint. In doing so, we also support healthcare professionals and patients with quality medical products and technology to raise standards and invigorate lives for tomorrow.

Our APAC Headquarters

A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD

30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787

 

2017

2017

  • 2017 - 09 - 27

    Carabinieri's CSI Department Has New Technology For Fighting Crime

    A new application for technology used in medicine has been discovered thanks to the collaboration between RIS (Reparto Investigazioni Scientifiche - Crime Scene Investigation Department) of the Carabinieri (Italian police) of Rome and Menarini. Destined to change the world of forensic science, this new technology application has even been published in the journal "Forensic Science International."
  • 2017 - 09 - 10

    COPD Increasing an Open Dialogue Between Patients and Physicians

    Milan (Italy) 10 September 2017: Perhaps due to the difficulty of admitting their illness, or perhaps because of a mere difference in terminology and language, 9 out of 10 patients with chronic obstructive pulmonary disease (COPD) do not inform their doctor of their real condition. A study1 published in the International Journal of COPD sheds light on the lack of effective, bi-directional communication which often affects the state of health of patients. The study will be present at the 2017 European Respiratory Society (ERS) Congress, to be held from 9 to 13 September in Milan.
  • 2017 - 03 - 27

    Selvita And Menarini Group announce Global License Agreement for Clinical Stage Oncology Drug PimFlt3 Inhibitor Sel24

    Krakow/Berlin, March 28, 2017 – Selvita S.A. (WSE:SLV), and Berlin-Chemie Menarini, a company of the Menarini Group, announced today that both companies have entered into a global license agreement for SEL24, a dual PIM/FLT3 inhibitor currently in Phase I/II trials in acute myeloid leukemia (AML) patients.
  • 2017 - 03 - 12

    Menarini arrives in Columbia and Peru

    The Menarini Group has consolidated its presence in Latin America with new affiliates in Colombia and Peru. Both countries have emerging economies which offer the company opportunities for market expansion with its high-quality pharmaceuticals. Two new affiliates have just been opened in Bogotá and Lima, strengthening the connection between two continents and creating a springboard for other areas of expansion in Latin America.
  • 2017 - 03 - 02

    Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries

    NEW HAVEN, Conn. and FLORENCE, Italy, March 1, 2017 – Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, and Menarini Group, an Italian biopharmaceutical group, today announced the signing of a development and commercialization agreement.
  • 2017 - 01 - 18

    Menarini in Turkey: + 25% Growth in 2016 and New Headquarters in Istanbul

    Florence, 18 January 2017: 25% is an impressive growth rate for Ibrahim Etem Menarini, the Turkish company of the Menarini Group, ranking 6th among the top pharma companies for the number of packages sold in a large and diverse market with a turnover of 410 million Turkish liras (125 million euros) and 800 employees.